EVX-01 Keeps Melanoma Patients Progression-Free at Three Years
EVAX sits 19% above its 52-week low of $2.72 on light trading volume (0.4× avg).
Summary
All followed patients in the Phase 2 EVX-01 melanoma trial held their prior responses at three years with no tumor progression, and year three was run as stand-alone therapy rather than on top of a PD-1 combo. That builds on the two-year data of 75% ORR and 25% complete responses, with 92% of responders still responding at two years. For a micro-cap with a lead asset and no partnership, durability is the main thing that makes the program licensable — a vaccine effect that persists off checkpoint inhibitors is a stronger story than combo data alone. The company flagged on October 2 that three-year immune data would be presented at SITC 2026 in November; this release front-runs that with the clinical durability readout. An ESMO 2026 poster on October 24 is the next scheduled public venue for the data.
At the time of this announcement, EVAX was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $2.72 to $11.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.